Summary

Other Scenarios:

Buyer: Neurocrine Biosciences, Inc. (NBIX) Last Price: 52.74 Market Cap.: 1.99B
Target: Medicis Pharmaceutical Corporation (MRX) Last Price: 31.50 Market Cap.: 1.71B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 861
Biopharmaceuticals 315
Medical Devices   247

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 21)
  • Urocortin 2
  • CRF R1 Antagonist
  • NBI-6024 (Altered Peptide Ligand)
  • NBI-5788 (Altered Peptide Ligand)
Target (Total: 20)
  • Novacet Lotion (Sodium Sulfacetamide/Sulfur)
  • Plexion/Plexion TS/Plexion SCT (Sodium Sulfacetamide/Sulfur)
  • Dynacin (Minocycline Hydrochloride)
  • Solodyn Extended Release Tablet (Minocycline HCl)
Buyer

n/a
Target
  • Restylane (Hyaluronic Acid)

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 2)
  • Pfizer Inc. (PFE)
  • Open Text Corporation (USA) (OTEX)
Target (Total: 6)
  • sanofi-aventis (ADR) (SNY)
  • Par Pharmaceutical Companies, Inc (PRX)
  • Q-Med, Inc. (QMED)
  • DPT Laboratories, Ltd.
Buyer (Total: 5)
  • Pfizer Inc. (PFE)
  • GlaxoSmithKline plc (ADR) (GSK)
  • Wyeth (WYE)
  • Eli Lilly & Co. (LLY)
Target (Total: 5)
  • McKesson Corporation (MCK)
  • Cardinal Health, Inc. (CAH)
  • AmerisourceBergen Corp. (ABC)
  • BioMarin Pharmaceutical (BMRN)

Key Financial Summary:

Metric Buyer Target
Number of Employees 564 356
Revenue Per Employee 139,496.5 889,246.7
Total Revenue 19.5 75.2
Total Expenses 47.1 166.5
Other Revenue 8.2 0.0
Cost of Revenue 0.0 12.2
SG&A Expense 19.3 51.2
Research & Development 27.7 97.2
Other Operating Expense 0.0 0.0
Operating Income -27.6 -91.3
Unusual Income 0.0 0.0
Gross Margin % 100 83.8
Metric Buyer Target
Operating Margin % -141.68 -121.5
Total Assets 477.4 1,002.0
Return on Equity % -27.6 -78.36
Cash+ ST Inv. Per Share 7.08 11.01
Total Debt 57.9 453.1
Curr Portion of LTD/Cap Lease 5.5 0.0
Total Debt to Equity 15.1 98.03
LT Debt to Capital 12.01 49.5
Fwd P/E 76.40 30.43
Fwd P/Rev 9.57 5.02
Book Value 383.8 462.2

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Biopharmaceuticals > Neurology

Target

Focused (): *Healthcare > Biopharmaceuticals > Dermatology

Business Description

Buyer

Neurocrine Biosciences, Inc. discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. The Company's product candidates address pharmaceutical markets in the world, including insomnia, anxiety, depression, various female and male health disorders, multiple sclerosis, diabetes and other neurological and endocrine related diseases and disorders. The Company has nine programs in various stages of research and development, including seven programs in clinical development. While the Company independently develops many of its product candidates, it has entered into collaborations for three of its programs. The Company's lead clinical development program, indiplon, is a drug for the treatment of insomnia. It has submitted two New Drug Applications (NDAs) to the United States Food and Drug Administration (FDA) with respect to indiplon.

Target

Medicis Pharmaceutical Corporation (Medicis) is an independent specialty pharmaceutical company focusing primarily on helping patients attain a healthy and youthful appearance and self-image through the development and marketing of products in the United States for the treatment of dermatologic, aesthetic and podiatric conditions in the United States and Canada. The Company offers a range of products addressing various conditions, including acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, eczema, skin and skin-structure infections, seborrheic dermatitis and cosmesis (improvement in the texture and appearance of skin). Medicis offers 15 branded products, including DYNACIN (minocycline HCI), LOPROX (ciclopirox), OMNICEF (cefdinir), PLEXION (sodium sulfacetamide/sulfur), RESTYLANE (hyaluronic acid), TRIAZ (benzoyl peroxide) and VANOS (fluocinonide) Cream 0.1%. On March 20, 2005, the Company entered into an agreement and plan of merger with Inamed Corporation.

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
  
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
  
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
  
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
  
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
  
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
  
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
  
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
  
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
  
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
  
Medical Devices  
Plastic/Reconstructive Surgery
The Plastic/Reconstructive Surgery Subsector includes medical devices that treat and modify a patient's external appearance.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Cardiovascular System  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Urocortin 2
  
Dermatology  
Acne  
Rosacea  
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat chronic inflammatory disorder of the face characterized by redness and pimple formation by inhibiting bacterial folic acid synthesis.

Target Products:

  • Novacet Lotion (Sodium Sulfacetamide/Sulfur)
  • Plexion/Plexion TS/Plexion SCT (Sodium Sulfacetamide/Sulfur)
  
Vulgaris  
Antibacterial Agents  
Tetracyclines
Therapeutics that treat acne caused by bacterial infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.

Target Products:

  • Dynacin (Minocycline Hydrochloride)
  • Solodyn Extended Release Tablet (Minocycline HCl)
  
Keratolytic Agents
Therapeutics that soften, separate, and cause the shedding of skin.

Target Products:

  • Triaz (Benzoyl Peroxide)
  
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat bacterial infections of the skin by inhibiting a bacterial enzyme responsible for synthesis of folic acid.

Target Products:

  • Novacet Lotion (Sodium Sulfacetamide/Sulfur)
  • Plexion/Plexion TS/Plexion SCT (Sodium Sulfacetamide/Sulfur)
  
Aging Disorders  
Photoaging  
Enzymatic Oxidation Inhibitors
Therapeutics composed of plant hormones that treat the effects on the skin of aging and sun exposure.

Target Products:

  • Lustra/Lustra-AF (Hydroquinone)
  
Wrinkles  
Acetylcholine Inhibitors
Therapeutics that treat wrinkling through prevention of muscle contractions that can result in the formation of facial lines.

Target Products:

  • Reloxin (Botulinum Toxin Type A)
  
Lesion/Scaling Disorders  
Dermatitis  
Atopic (Eczema)  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat atopic dermatoses by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Target Products:

  • Vanos (Fluocinonide)
  • Synalar (Fluocinolone Acetonide)
  
Seborrheic (Dandruff)  
Antifungal Agents  
Imidazoles
Therapeutics that treat and prevent skin diseases caused by fungi.

Target Products:

  • Loprox (Ciclopirox)
  
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat bacterial infections of the skin by inhibiting a bacterial enzyme responsible for synthesis of folic acid.

Target Products:

  • Novacet Lotion (Sodium Sulfacetamide/Sulfur)
  • Plexion/Plexion TS/Plexion SCT (Sodium Sulfacetamide/Sulfur)
  
Dermatoses  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Target Products:

  • Topicort/Topicort LP (Desoximetasone)
  • Lidex (Fluocinonide)
  • Vanos (Fluocinonide)
  
Pruritus  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Target Products:

  • Vanos (Fluocinonide)
  
Psoriasis  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Target Products:

  • Vanos (Fluocinonide)
  • Synalar (Fluocinolone Acetonide)
  
Pigmentation Disorders  
Hyperpigmentation  
Enzymatic Oxidation Inhibitors
Therapeutics that treat disorders characterized by darkening of the skin by inhibiting metabolic processes of pigment producing skin cells.

Target Products:

  • Alustra (Hydroquinone)
  • Esoterica (Hydroquinone)
  
Digestive System  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • CRF R1 Antagonist
  
Endocrinology/Metabolism
Intermediary Metabolism Disorders  
Urea Cycle Disorders  
Glutamine Acetylyzing Agents
Therapeutics that conjugate with glutamine to help excrete nitrogen waste.

Target Products:

  • Ammonul (Sodium Phenylacetate, Sodium Benzoate)
  • Buphenyl (Sodium Phenylbutyrate)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • NBI-6024 (Altered Peptide Ligand)
  
Immunology
Autoimmune Disorders  
Psoriasis  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat a chronic autoimmune disease characterized by softening, separating, causing the shedding of the horny layer of the skin with a steroidal compound.

Target Products:

  • Vanos (Fluocinonide)
  • Synalar (Fluocinolone Acetonide)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • NBI-5788 (Altered Peptide Ligand)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • CCR7
  
Infectious Diseases  
Arachnids  
Lice  
Cholinesterase Inhibitors
Therapeutics that treat Lice by inhibiting the break down of acetylcholine.

Target Products:

  • Ovide (Malathion)
  
Bacterial  
Antibacterial Agents  
Broad Spectrum  
Antibiotics  
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.

Target Products:

  • Omnicef (Cefdinir)
  
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.

Target Products:

  • Dynacin (Minocycline Hydrochloride)
  
Mycological (Fungal)  
Antifungal Agents  
Narrow Spectrum  
Dermatology  
Tinea Corporis (Ringworm)  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Target Products:

  • Loprox (Ciclopirox)
  
Tinea Cruris (Jock Itch)  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the groin and perineum by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Target Products:

  • Loprox (Ciclopirox)
  
Tinea Pedis  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the feet by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Target Products:

  • Loprox (Ciclopirox)
  
Tinea Versicolor  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of skin exposed to the sun characterized by patches of depigmentation by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Target Products:

  • Loprox (Ciclopirox)
  
Neurology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • NBI-75043
  • NBI-34041 (CRF R1 Antagonist)
  • NBI-5788 (Altered Peptide Ligand)
  • CRF R1 Antagonist
  
Psychiatric Disorders  
Sleep Disorders  
Insomnia  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.

Buyer Products:

  • Indiplon Immediate Release Capsule
  • Indiplon Modified Release Tablet
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Adenosine 2A Receptor Antagonists
  • Sleep Program
  • Excitatory Amino Acid Transporters
  • CRF R2 Antagonist
  • MC-4 (Melanin Concentrating Hormone Antagonist)
  • Melanocortin Receptor Agonist
  
Obstetrics/Gynecology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • D2 Receptor Agonist
  • NBI-56418 (GnRH Antagonist)
  • NBI-42902 (GnRH Antagonist)
  
Oncology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Buyer Products:

  • NBI-42902 (GnRH Antagonist)
  • NBI-3001 (IL-4 Fusion Toxin)
  
Pain Management  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of pain in very early stages of research where no human subject is involved.

Buyer Products:

  • Fractalkine
  
Respiratory System  
Lower Respiratory Tract Disorders (Lung Disorders)  
Asthma  
Acute Treatments  
Bronchodilators  
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.

Target Products:

  • Pediavent (Albuterol)
  
Urology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • D2 Receptor Agonist
  • NBI-56418 (GnRH Antagonist)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • MC-4 (Melanin Concentrating Hormone Antagonist)
  
Weight Management  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • MC-4 (Melanin Concentrating Hormone Antagonist)
  • Melanocortin Receptor Antagonist
  • Melanocortin Receptor Agonist
  
Medical Devices  
Plastic/Reconstructive Surgery  
Treatment  
Wrinkle Removal  
Hyaluronic Acid  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Pfizer Inc. n/a 179,521.061 15.19 12.28 3.53 3.54 10.09
GlaxoSmithKline plc (ADR) n/a 165,878.661 17.69 17.38 3.93 3.96 18.50
sanofi-aventis (ADR) n/a 133,880.824 47.13 13.63 3.72 3.79 n/a
Wyeth n/a 65,776.529 17.72 15.66 3.46 3.25 7.34
Bristol Myers Squibb Co. n/a 47,761.793 14.99 20.69 2.47 2.53 10.22
Schering AG (ADR) n/a 20,873.552 25.05 25.69 2.96 n/a 5.77
Elan Corporation, plc (ADR) n/a 6,801.639 n/a -18.73 13.03 10.07 -10.61
King Pharmaceuticals n/a 4,396.073 44.83 12.63 2.33 2.45 4.68
Buyer
  Pfizer Inc. n/a 179,521.061 15.19 12.28 3.53 3.54 10.09
GlaxoSmithKline plc (ADR) n/a 165,878.661 17.69 17.38 3.93 3.96 18.50
Target
  Pfizer Inc. n/a 179,521.061 15.19 12.28 3.53 3.54 10.09
Johnson & Johnson n/a 174,197.162 16.24 15.99 3.44 3.30 6.17
GlaxoSmithKline plc (ADR) n/a 165,878.661 17.69 17.38 3.93 3.96 18.50
sanofi-aventis (ADR) n/a 133,880.824 47.13 13.63 3.72 3.79 n/a
Wyeth n/a 65,776.529 17.72 15.66 3.46 3.25 7.34
Bristol Myers Squibb Co. n/a 47,761.793 14.99 20.69 2.47 2.53 10.22
Schering-Plough Corp. n/a 28,258.433 66.11 30.30 2.92 2.82 3.94
Schering AG (ADR) n/a 20,873.552 25.05 25.69 2.96 n/a 5.77
Allergan, Inc. n/a 14,597.291 n/a 26.60 6.06 4.99 45.55
Altana AG (ADR) n/a 8,415.800 15.27 14.53 2.05 n/a 5.08
Elan Corporation, plc (ADR) n/a 6,801.639 n/a -18.73 13.03 10.07 -10.61
King Pharmaceuticals n/a 4,396.073 44.83 12.63 2.33 2.45 4.68
Mentor Corporation n/a 1,855.362 30.50 30.36 3.70 3.72 9.27
Valeant Pharmaceuticals International n/a 1,565.539 n/a 47.53 1.86 1.80 -9.50
First Horizon Pharmaceutical Corp. n/a 825.620 19.30 20.88 3.41 3.01 20.50

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Pfizer Inc. n/a 179,521.061 15.19 12.28 3.53 3.54 10.09
Open Text Corporation (USA) n/a 713.679 393.02 15.40 1.73 1.75 8.73
Target
  sanofi-aventis (ADR) n/a 133,880.824 47.13 13.63 3.72 3.79 n/a
Par Pharmaceutical Companies, Inc n/a 784.559 n/a 20.32 1.54 1.20 2.26
Q-Med, Inc. n/a 101.812 432.29 204.33 4.95 2.48 4.42
DPT Laboratories, Ltd. n/a n/a n/a n/a n/a n/a n/a
Contract Pharmaceuticals Limited n/a n/a n/a n/a n/a n/a n/a
Patheon Inc. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Pfizer Inc. 90.80% 179,521.061 15.19 12.28 3.53 3.54 10.09
GlaxoSmithKline plc (ADR) 9.20% 165,878.661 17.69 17.38 3.93 3.96 18.50
Wyeth n/a 65,776.529 17.72 15.66 3.46 3.25 7.34
Eli Lilly & Co. n/a 57,003.803 27.53 16.28 3.84 3.73 4.87
Taisho Pharmaceuticals Co. Ltd. n/a n/a n/a n/a n/a n/a n/a
Target
  McKesson Corporation 51.20% 14,632.871 19.31 18.30 0.17 0.16 3.73
Cardinal Health, Inc. 21.80% 27,758.866 29.94 21.57 0.35 0.35 7.37
AmerisourceBergen Corp. n/a 9,231.394 27.03 21.13 0.16 0.16 4.86
BioMarin Pharmaceutical n/a 1,065.277 n/a -25.98 30.89 17.87 108.60
Quality King Distributors n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Pfizer Inc. n/a 179,521.061 15.19 12.28 3.53 3.54 10.09
GlaxoSmithKline plc (ADR) n/a 165,878.661 17.69 17.38 3.93 3.96 18.50
Wyeth n/a 65,776.529 17.72 15.66 3.46 3.25 7.34
Eli Lilly & Co. n/a 57,003.803 27.53 16.28 3.84 3.73 4.87
Biosite Incorporated n/a 819.734 15.51 20.96 2.78 2.61 2.67
DOV Pharmaceutical, Inc. n/a 165.879 n/a -2.70 19.18 10.02 -8.59
Pharmacopeia Drug Discovery, Inc. n/a 78.860 n/a -7.47 3.87 3.76 2.24
Deltagen, Inc. n/a 23.311 n/a n/a 3.48 n/a 2.40
Taisho Pharmaceuticals Co. Ltd. n/a n/a n/a n/a n/a n/a n/a
Almirall Prodesfarma, S.A. n/a n/a n/a n/a n/a n/a n/a
Target
  sanofi-aventis (ADR) n/a 133,880.824 47.13 13.63 3.72 3.79 n/a
Abbott Laboratories n/a 63,215.948 18.80 16.88 2.86 2.88 13.96
Cardinal Health, Inc. n/a 27,758.866 29.94 21.57 0.35 0.35 7.37
McKesson Corporation n/a 14,632.871 19.31 18.30 0.17 0.16 3.73
AmerisourceBergen Corp. n/a 9,231.394 27.03 21.13 0.16 0.16 4.86
BioMarin Pharmaceutical n/a 1,065.277 n/a -25.98 30.89 17.87 108.60
Par Pharmaceutical Companies, Inc n/a 784.559 n/a 20.32 1.54 1.20 2.26
Taro Pharmaceutical Industries Ltd. n/a 350.368 20.22 15.82 1.16 1.16 0.91
Q-Med, Inc. n/a 101.812 432.29 204.33 4.95 2.48 4.42
Beaufour Ipsen Group n/a n/a n/a n/a n/a n/a n/a
DPT Laboratories, Ltd. n/a n/a n/a n/a n/a n/a n/a
Contract Pharmaceuticals Limited n/a n/a n/a n/a n/a n/a n/a
Dow Pharmaceutical Sciences, Inc. n/a n/a n/a n/a n/a n/a n/a
Patheon Inc. n/a n/a n/a n/a n/a n/a n/a
Quality King Distributors n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 102.3 339.7 441.9
Other Revenue 29.2 0.0 29.2
Total Revenue 131.5 339.7 471.2
Cost of Revenue 0.0 50.6 50.6
SG&A Expense 56.1 179.4 235.5
Depreciation & Amortization 0.0 24.4 24.4
Research & Development 108.8 124.3 233.1
Interest Expense 0.0 0.0 0.0
Other Operating Expense 0.0 0.0 0.0
Total Expenses 164.8 378.6 543.5
Operating Income -33.3 -39.0 -72.3
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 4.1 9.8 13.9
Other, Net 0.0 59.8 59.8
Income Before Taxes -29.3 30.7 1.4
Income Taxes 0.0 45.1 45.1
Income After Taxes -29.3 -14.4 -43.7
Net Income - Excl. Xord. Items -29.3 -14.4 -43.7
Net Income - Incl. Xord. Items -29.3 -14.4 -43.7
Income Avail. to Common -29.3 -14.4 -43.7
Share Items
Basic Avg. Shares Outstanding 37.4 54.4 91.7
Basic EPS - Excl. Xord. Items -0.78 -0.27 -0.48
Basic EPS - Incl. Xord. Items -0.78 -0.27 -0.48
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 37.4 54.4 91.7
F.D. EPS - Excl. Xord. Items -0.81 -0.49 -0.48
F.D. EPS - Incl. Xord. Items -0.81 -0.49 -0.48
Dividends Per Common Share 0.00 0.12 0.12
Balance Sheet
Assets
Cash and Equivalents 101.5 245.8 347.3
ST Investments 163.0 352.9 515.9
Accounts Receivable 5.9 50.4 56.3
Inventory 0.0 15.7 15.7
Other Current Assets 4.3 25.5 29.8
Current Assets 274.7 690.3 965.0
Accum D&A 0.0 0.0 0.0
PPE, Net 97.4 5.0 102.4
Goodwill & Intangibles 0.0 298.2 298.2
Other Assets 0.0 0.0 0.0
Other LT Assets 105.3 8.5 113.8
Total Assets 477.4 1,002.0 1,479.4
Liabilities
Accounts Payable 0.0 35.8 35.8
Payable/Accrued 16.8 0.0 16.8
ST Debt 0.0 0.0 0.0
Curr Port of LTD & Cap Lease Oblg 5.5 0.0 5.5
Other (Current) Liabilities 10.4 39.3 49.7
Current Liab. 32.8 75.0 107.8
LT Debt 0.0 453.1 453.1
Capitalized Lease Obligations 52.4 0.0 52.4
Total LT Debt 52.4 453.1 505.5
Deferred Taxes 0.0 11.7 11.7
Other LT Liab. 8.4 0.0 8.4
Total Liabilities 93.6 539.8 633.4
Shareholders Equity
Common Stock 0.0 0.9 1.0
Additional Paid in Capital 711.0 557.8 1,268.8
Retained Earnings -326.0 244.7 -81.3
Treasure Stock 0.0 -342.7 -342.7
Other Equity -1.2 1.5 0.3
Total Equity 383.8 462.2 846.0
Total Liab. & Equity 477.4 1,002.0 1,479.4
Shares Outstanding 37.7 54.4 92.1
Cash Flow
Operating Cash Flow
CF Net Income -29.3 -14.4 -43.7
CF Depreciation 10.3 24.9 35.2
CF Deferred Taxes 0.0 10.6 10.6
Other Non-Cash Items -14.1 24.2 10.1
Change in Working Capital 7.9 41.8 49.7
Total Cash From Operating Activities -25.2 87.1 61.9
Investing Cash Flow
Capital Expenditures -6.4 -2.6 -9.0
Other Investing Cash Flows 64.8 97.8 162.6
Total Cash From Investing Activities 58.4 95.2 153.6
Financing Cash Flow
Dividends Paid 0.0 -6.6 -6.6
Purchase Or Sale of Stock 30.1 1.8 31.9
Purchase and Retirement of Debt -6.5 0.0 -6.5
Other Financing Cash Flow 0.1 0.1 0.2
Total Cash From Financing Activities 23.7 -4.7 19.0
Exchange Rate Effects 0.0 0.0 0.0
Net Change in Cash 56.9 177.6 234.5
Cash Taxes Paid 0.0 13.9 13.9
Cash Interest Paid 4.5 0.0 4.5